摘要
心房颤动是较常见的一种心律失常,目前新型口服抗凝药(NOACs)已逐渐取代华法林,成为房颤患者的首选治疗药物,其中利伐沙班的使用比较普遍,但临床上使用利伐沙班时,利伐沙班的血药浓度可分布在400 ng/ml的范围内,且谷值范围和峰值范围相当大,甚至出现重叠区域。此外,随着一些无法解释的药品安全事件的出现,很可能由于利伐沙班极低的谷浓度和极高的峰浓度使部分患者面临血栓或出血的风险。本研究通过系统回顾心房颤动患者服用利伐沙班致导致出血的国内外研究,阐述目前的研究进展。
Atrial fibrillation is a common arrhythmia, the new oral anticoagulants (NOACs) has gradually re-placed warfarin, becomes the preferred treatment of patients with atrial fibrillation, the use of rivaroxaban is more common, but clinical use of rivaroxaban, rivaroxaban drug concentration can be distributed in400 ng/ml, and the valley range and peak range is quite large, and even overlapping areas. Furthermore, with the emergence of some unexplained drug safety events, it is likely that some patients are at risk of thrombosis or bleeding due to the extremely low trough concentrations and extremely high peak concentrations of rivaroxaban. This study presents the current progress through a systematic review of domestic and foreign studies of rivaroxaban.
出处
《临床医学进展》
2023年第12期20291-20296,共6页
Advances in Clinical Medicine
